Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.
Following court injunctions, some states and cities regained funding, while others experienced continued cancellations that affected immunization clinics, workforce capacity, and infectious-disease surveillance.
Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.